Eledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 1.5% – What’s Next?

Posted by Stanley Muller on Sep 25th, 2026

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Free Report)’s share price dropped 1.5% during mid-day trading on Thursday. The company traded as low as $2.60 and last traded at $2.68. 1,029,520 shares were traded during trading, an increase of 10% from the average session volume of 937,334 shares. The stock had previously closed at $2.72.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELDN. Weiss Ratings reissued a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Monday. Wall Street Zen cut shares of Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 23rd. Finally, Rodman & Renshaw started coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, July 21st. They set a “buy” rating and a $12.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Get Our Latest Research Report on Eledon Pharmaceuticals

Eledon Pharmaceuticals Trading Down 1.5%

The firm has a market cap of $217.78 million, a P/E ratio of -2.95 and a beta of 0.93. The firm’s 50 day moving average is $3.28 and its two-hundred day moving average is $3.45.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.11). Analysts predict that Eledon Pharmaceuticals, Inc. will post -0.74 EPS for the current fiscal year.

Institutional Trading of Eledon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ELDN. Legal & General Group Plc acquired a new position in shares of Eledon Pharmaceuticals in the second quarter valued at approximately $28,000. SG Americas Securities LLC raised its holdings in shares of Eledon Pharmaceuticals by 1.3% during the first quarter. SG Americas Securities LLC now owns 635,845 shares of the company’s stock worth $1,958,000 after acquiring an additional 8,453 shares during the period. Grandfield & Dodd LLC acquired a new stake in shares of Eledon Pharmaceuticals during the second quarter worth $39,000. Susquehanna Fundamental Investments LLC bought a new stake in Eledon Pharmaceuticals in the 2nd quarter valued at $43,000. Finally, Bank of New York Mellon Corp lifted its position in Eledon Pharmaceuticals by 8.5% in the 1st quarter. Bank of New York Mellon Corp now owns 144,148 shares of the company’s stock valued at $444,000 after acquiring an additional 11,246 shares in the last quarter. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies that modulate the immune system to address organ and cell transplantation, autoimmune disease, and other immune-mediated conditions. The company’s approach is designed to promote immune tolerance while reducing the need for conventional immunosuppressive treatments.

Eledon’s lead product candidate is tegoprubart, an investigational monoclonal antibody that targets the CD40 ligand (CD40L) pathway.